Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Therapeutics

Background:

• Modern chemotherapy and supportive care improve survival for pediatric acute myeloid leukemia (AML) to over 60%.
• Primary refractory or relapsed pediatric AML presents significant challenges, leading to high morbidity and mortality.
• Current long-term survival rates for relapsed or refractory pediatric AML remain poor despite treatment efforts.

Purpose of the Study:

• To review the scope of relapsed and refractory pediatric AML.
• To discuss current and emerging chemotherapy options for this patient population.
• To highlight the urgent need for improved understanding and refined treatment protocols.

Main Methods:

• This is a review article.
• The review discusses existing literature on relapsed and refractory pediatric AML.
• It examines current and novel therapeutic strategies.

Main Results:

• Relapsed or refractory pediatric AML continues to be a major cause of treatment failure.
• While some patients achieve remission, long-term survival is not significantly improved.
• Achieving complete remission without dose-limiting toxicities is a primary goal, followed by hematopoietic stem cell transplantation.

Conclusions:

• There is a critical need for better therapeutic strategies for relapsed and refractory pediatric AML.
• Ongoing research focuses on identifying therapies to improve overall survival (OS).
• The ultimate aim is to enhance outcomes for children with refractory or relapsed AML through novel treatments and transplantation.